146 related articles for article (PubMed ID: 35118633)
21. Activation of the TGF-β1/Smad signaling by KIF2C contributes to the malignant phenotype of thyroid carcinoma cells.
Lin Q; Qi Q; Hou S; Chen Z; Jiang N; Zhang L; Lin C
Tissue Cell; 2021 Dec; 73():101655. PubMed ID: 34624565
[TBL] [Abstract][Full Text] [Related]
22. Taraxasterol inhibits TGF-β1-induced epithelial-to-mesenchymal transition in papillary thyroid cancer cells through regulating the Wnt/β-catenin signaling.
Zhu J; Li X; Zhang S; Liu J; Yao X; Zhao Q; Kou B; Han P; Wang X; Bai Y; Zheng Z; Xu C
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S87-S95. PubMed ID: 34219514
[TBL] [Abstract][Full Text] [Related]
23. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma.
Lammerts E; Roswall P; Sundberg C; Gotwals PJ; Koteliansky VE; Reed RK; Heldin NE; Rubin K
Int J Cancer; 2002 Dec; 102(5):453-62. PubMed ID: 12432546
[TBL] [Abstract][Full Text] [Related]
24. Interferon-gamma differentially regulates TGF-beta1 and TGF-beta2 expression in human retinal pigment epithelial cells through JAK-STAT pathway.
Nagineni CN; Cherukuri KS; Kutty V; Detrick B; Hooks JJ
J Cell Physiol; 2007 Jan; 210(1):192-200. PubMed ID: 17013806
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of TGF-β 1 expression in patients with thyroidectomy.
Li J; Wei F
Cancer Biomark; 2015; 15(5):693-8. PubMed ID: 26406959
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA
Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894
[TBL] [Abstract][Full Text] [Related]
27. Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors.
Zurawa-Janicka D; Kobiela J; Galczynska N; Stefaniak T; Lipinska B; Lachinski A; Skorko-Glonek J; Narkiewicz J; Proczko-Markuszewska M; Sledzinski Z
Oncol Rep; 2012 Nov; 28(5):1838-44. PubMed ID: 22923201
[TBL] [Abstract][Full Text] [Related]
28. Transforming growth factor beta1 regulates follistatin mRNA expression during in vitro bovine granulosa cell differentiation.
Fazzini M; Vallejo G; Colman-Lerner A; Trigo R; Campo S; Barañao JL; Saragüeta PE
J Cell Physiol; 2006 Apr; 207(1):40-8. PubMed ID: 16245315
[TBL] [Abstract][Full Text] [Related]
29. Disrupted transforming growth factor-beta signaling and deregulated growth in human biliary tract cancer cells.
Yazumi S; Ko K; Watanabe N; Shinohara H; Yoshikawa K; Chiba T; Takahashi R
Int J Cancer; 2000 Jun; 86(6):782-9. PubMed ID: 10842191
[TBL] [Abstract][Full Text] [Related]
30. Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance.
Gao H; Bai P; Xiao L; Shen M; Yu Q; Lei Y; Huang W; Lin X; Zheng X; Wei T; Jiang Y; Ye F; Bu H
J Biol Chem; 2020 Jul; 295(31):10726-10740. PubMed ID: 32532820
[TBL] [Abstract][Full Text] [Related]
31. Curcumin inhibits metastasis in human papillary thyroid carcinoma BCPAP cells via down-regulation of the TGF-β/Smad2/3 signaling pathway.
Zhang L; Cheng X; Gao Y; Zhang C; Bao J; Guan H; Yu H; Lu R; Xu Q; Sun Y
Exp Cell Res; 2016 Feb; 341(2):157-65. PubMed ID: 26826337
[TBL] [Abstract][Full Text] [Related]
32. Side population cells in anaplastic thyroid cancer and normal thyroid.
Mahkamova K; Latar NM; Aspinall S; Meeson A
Exp Cell Res; 2019 Jan; 374(1):104-113. PubMed ID: 30465733
[TBL] [Abstract][Full Text] [Related]
33. Transforming Growth Factor-beta 1 Involved in the Pathogenesis of Endometriosis through Regulating Expression of Vascular Endothelial Growth Factor under Hypoxia.
Yu YX; Xiu YL; Chen X; Li YL
Chin Med J (Engl); 2017 Apr; 130(8):950-956. PubMed ID: 28397725
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Zhang X; Liu L; Deng X; Li D; Cai H; Ma Y; Jia C; Wu B; Fan Y; Lv Z
Oncogene; 2019 Jan; 38(5):699-715. PubMed ID: 30171257
[TBL] [Abstract][Full Text] [Related]
35. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
Deng X; Bellis S; Yan Z; Friedman E
Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
[TBL] [Abstract][Full Text] [Related]
36. Effect of transforming growth factor-beta on decorin and beta1 integrin expression during muscle development in chickens.
Li X; McFarland DC; Velleman SG
Poult Sci; 2006 Feb; 85(2):326-32. PubMed ID: 16523634
[TBL] [Abstract][Full Text] [Related]
37. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1.
Kalembeyi I; Inada H; Nishiura R; Imanaka-Yoshida K; Sakakura T; Yoshida T
Int J Cancer; 2003 May; 105(1):53-60. PubMed ID: 12672030
[TBL] [Abstract][Full Text] [Related]
38. Growth inhibition after exposure to transforming growth factor-β1 in human bladder cancer cell lines.
Lee C; Lee SH; Kim DS; Jeon YS; Lee NK; Lee SE
Korean J Urol; 2014 Jul; 55(7):487-92. PubMed ID: 25045449
[TBL] [Abstract][Full Text] [Related]
39. TGF-beta1 perturbs vascular development and inhibits epithelial differentiation in fetal lung in vivo.
Zeng X; Gray M; Stahlman MT; Whitsett JA
Dev Dyn; 2001 Jul; 221(3):289-301. PubMed ID: 11458389
[TBL] [Abstract][Full Text] [Related]
40. Activin A and activin receptors in thyroid cancer.
Schulte KM; Jonas C; Krebs R; Röher HD
Thyroid; 2001 Jan; 11(1):3-14. PubMed ID: 11272093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
